TrialSignal
Clinical trial intelligence report
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT07179653
Status
ACTIVE_NOT_RECRUITING
Phase
PHASE2
Sponsor
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Executive brief
Investment-Ready Snapshot
The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in subjects with HBSAg levels of 0.05 to 100 IU/mL, including CHB patients previously treated with siRNA/ASO drugs and treatment-naive HBV infection.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07179653
Indication
HBV Infection
Modality
small molecule
Target
TVAX-008, Placebo
Intervention
TVAX-008, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.